ArticleMedical archives (Sarajevo, Bosnia and Herzegovina)2025
Role of Anti-Vinculin Quantitative ELISA Test in Diagnosing Irritable Bowel Syndrome and Inflammatory Bowel Disease.
Article in Medical archives (Sarajevo, Bosnia and Herzegovina), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Vinculin is a cytoplasmic protein that binds to actin and is involved in cell adhesion. The presence of anti-vinculin autoantibodies in irritable bowel syndrome (IBS) is consistent with prior studies which have implicated vinculin as an important regulator of the enteric nervous system. Objective: Therefore, in this study, we developed a testing protocol and optimized it before evaluating the value of the Anti-Vinculin quantitative test in the diagnosis of IBD and IBS. Methods: To establish the procedure for quantification of anti-vinculin antibody (ATV) in serum by indirect ELISA and to investigate value of anti-vinculin testing in diagnosing irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). Results: After optimizing the procedure for ATV quantitative ELISA, we conducted the tests to determine the concentration of ATV in serum specimens. In this research, we use ATV results from 215 patients with IBS, 71 patients with IBD and 31 healthy subjects and assessed utility of ATV as a diagnostic test for IBS and to differentiate between IBS and IBD. On testing for ATV in patients with IBS and IBD, we found that it has potential for diagnosing patients with IBS, with an area under the curve (AUC) of 0.76, p <0.001With a cut-off of ATV concentration at 510.59 ng/mL, sensitivity of test was 48.8%, and specificity was 96.8%. Conclusion: The model of using ATVs to differentiate between IBD and IBS had not given optimal results. Further research is needed with larger sample sizes and uniformity among groups to come up with an effective model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.